© 2005-2012 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.
Cancer.Net Specialty Editor: Childhood Cancers
University of Minnesota Cancer Center, Minneapolis, MN
Brenda Weigel, MD, is the Director of the Division of Pediatric Hematology/Oncology and is an Associate Professor cross-appointed at the University of Minnesota's Cancer Center and the Department of Pediatrics, and the recipient of the Lehman/Children's Cancer Research Fund Endowed Chair in Pediatric Cancer. She is also the Co-Director of the Sarcoma Program for the Masonic Cancer Center, and an Associate Director of the Cancer Experimental Therapeutics Initiative for the Masonic Cancer Center. Dr. Weigel is the medical director of the Masonic Cancer Center Clinical Trials Office.
Dr. Weigel received her medical degree from McMaster University in Hamilton, Ontario, and conducted her residency in pediatrics at the University of Western Ontario. She came to the University of Minnesota in 1996 to conduct a fellowship in Pediatric Hematology/Oncology and Bone Marrow Transplant. During her four-year fellowship, Dr. Weigel worked in the laboratory of Bruce Blazar, MD, and developed a murine model of rhabdomyosarcoma.
Dr. Weigel's major interests have been advancing new therapies, particularly therapies that harness the immune system's role in fighting cancer. Her research interests are centered in her extensive involvement with the Children's Oncology Group (COG). She is the Vice Chair of Developmental Therapeutics, Co-chair for New High Risk Rhabdomyosarcoma Study, Chair for Phase II Study of IGFR Antibody, and Chair for a High Risk Rhabdomyosarcoma Study.
Last Updated: May 24, 2012